|
|
November 26, 2024 -Tuesday |
|
|
|
|
|
|
MALAYSIA BECOMES FIRST CATALYST SITE NETWORK IN ASIA PACIFIC FOR CLINICAL RESEARCH WITH SYNEOS HEALTH
Friday 23/12/2022
PUTRAJAYA, Dec 23 (Bernama) -- Clinical Research Malaysia (CRM) signed a charter agreement earlier today with Syneos Health, the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, formalizing the inclusion of CRM-affiliated clinical research sites under the Syneos Health Catalyst Program. The Syneos Health Catalyst Program brings together clinical research sites and industry partners to deliver consistent quality in clinical trials. Sites under the program have the opportunity to participate in an increased volume of clinical trials as well as harness best practices and insights from other clinical research sites across the globe. With the inking of this partnership, research sites in Malaysia will form Syneos Health’s first Catalyst Site Network in the Asia Pacific region. Sites within the network would benefit from increased access to clinical trials managed by Syneos Health in addition to improved efficiencies in study operations. The charter agreement was signed at the Ministry of Health office in Putrajaya between General Manager and Regional Head of Asia Pacific Dr Ken Lee and Chief Executive Officer of Clinical Research Malaysia (CRM) Dr Akhmal Yusof. It was witnessed by the Minister of Health, YB Dr Zaliha Mustafa. Prior to the signing, YB Dr Zaliha delivered her address, sharing her aspirations from the new collaboration. “This partnership is one of the many ongoing efforts by CRM to strengthen the country’s clinical research footprints. With more than 2000 sponsored clinical research conducted since 2012 in Malaysia, this collaboration would unlock new opportunities in bettering the quality of clinical trials and discovery of new treatment and local drugs.”, said YB Dr Zaliha. “Because of Malaysia’s clinical research achievements, it is natural for Syneos Health to be drawn here. We are seeing key drivers such as the start of the next wave of oncology biosimilars and cell and gene therapies put pressure on delivery. It is becoming essential we look to work with countries such as Malaysia in accelerating these new therapies to patients worldwide. A key part of this is to set up the framework of Catalyst in Malaysia.”, added Dr Ken Lee. About Clinical Research Malaysia (CRM) Established by Malaysian Ministry of Health in 2012, Clinical Research Malaysia exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provides the organisation an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high-skilled job opportunities. Source: Clinical Research Malaysia (CRM)
FOR MORE INFORMATION, PLEASE CONTACT: Name: Asha Thanabalan Tel: +6012- 364 8043 E-mail: asha@clinicalresearch.my --BERNAMA |
|
|
|
|
|